Browse Penn-owned technologies available for licensing.
This invention consists of the antibody directed against RGS12, delivered with or without nanoparticles that can be injected into the affected joints or systematically. Upon delivery, the antibody blocks the bone resorption and inflammatory activities, resulting in less painful swelling and increased bone density and protect bone erosion.
In mouse models, the anti-inflammatory effects of this therapy are shown to be more effective than the current standard of care, Celecoxib. This technology’s antibody-based treatment also causes fewer side effects and is less toxic than conventional drugs. RA patients and those suffering from osteoporosis could see improved outcomes with this therapy.